The estimated Net Worth of Michael Arenberg is at least $491 ezer dollars as of 12 March 2019. Mr Arenberg owns over 10,000 units of Durect Corp stock worth over $38,349 and over the last 6 years he sold DRRX stock worth over $0. In addition, he makes $452,940 as CFO & Sec. at Durect Corp.
Mr has made over 1 trades of the Durect Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of DRRX stock worth $8,000 on 12 March 2019.
The largest trade he's ever made was buying 10,000 units of Durect Corp stock on 12 March 2019 worth over $8,000. On average, Mr trades about 1,667 units every 0 days since 2018. As of 12 March 2019 he still owns at least 24,426 units of Durect Corp stock.
You can see the complete history of Mr Arenberg stock trades at the bottom of the page.
Michael H. Arenberg is the CFO & Sec. at Durect Corp.
As the CFO & Sec. of Durect Corp, the total compensation of Mr Arenberg at Durect Corp is $452,940. There are 1 executives at Durect Corp getting paid more, with Dr. James E. Brown D.V.M. having the highest compensation of $775,884.
Mr Arenberg is 51, he's been the CFO & Sec. of Durect Corp since . There are 4 older and no younger executives at Durect Corp. The oldest executive at Durect Corp is Dr. Su Il Yum Ph.D., 82, who is the Exec. Officer.
Michael's mailing address filed with the SEC is C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO, CA, 95014.
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management... és Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Durect Corp executives and other stock owners filed with the SEC include: